Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Prime Medicine, Inc. (NASDAQ: PRME)
PRME Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7.70%
Analyst Rating:
BUY
Analyst Forecast (1yr):
172%
PRME Stock Analysis
PRME
PE Ratio:
PRME
PEG Ratio:
Not Available
PRME
Forward EPS Growth (12 month):
0.00%
PRME
PS Ratio:
140.6
PRME
PSG Ratio:
3.3
PRME
Forward Revenue Growth (12 month):
42.60%
PRME Articles
No data was found